Axonics, Inc. (AXNX)

Market Cap	3.39B
Revenue (ttm)	366.38M
Net Income (ttm)	-6.09M
Shares Out	51.00M
EPS (ttm)	-0.12
PE Ratio	n/a
Forward PE	177.32
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,058,533
Open	66.75
Previous Close	66.84
Day's Range	66.42 - 66.79
52-Week Range	47.59 - 69.68
Beta	0.59
Analysts	Hold
Price Target	71.25 (+7.19%)
Earnings Date	May 7, 2024

About AXNX

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to r...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Raymond W. Cohen
• Employees: 797
• Stock Exchange: NASDAQ
• Ticker Symbol: AXNX

Financial Performance

In 2023, Axonics's revenue was $366.38 million, an increase of 33.86% compared to the previous year's $273.70 million. Losses were -$6.09 million, -89.80% less than in 2022.

Analyst Forecast

According to 11 analysts, the average rating for AXNX stock is "Hold." The 12-month stock price forecast is $71.25, which is an increase of 7.19% from the latest price.

Price Target

$71.25

(7.19% upside)

Analyst Consensus: Hold